Shares in Ranbaxy Laboratories gained as much as 3.3 per cent, after falling 26 per cent over Friday and Monday following a ban by U.S. drug regulator on more of its products.
"Valuation wise, the stock looks good at these levels. It has fallen a lot and I don't think it will fall beyond 300 rupees," said Suresh Parmar, head, institutional equities at KJMC Capital Markets.
At 10:34 a.m., shares in Ranbaxy were up 2.41 per cent at Rs. 316.60 rupees, outperforming the broader Nifty, which was up 0.24 per cent.
"Valuation wise, the stock looks good at these levels. It has fallen a lot and I don't think it will fall beyond 300 rupees," said Suresh Parmar, head, institutional equities at KJMC Capital Markets.
At 10:34 a.m., shares in Ranbaxy were up 2.41 per cent at Rs. 316.60 rupees, outperforming the broader Nifty, which was up 0.24 per cent.
0 comments:
Post a Comment